Arrowhead Pharmaceuticals (NASDAQ: ARWR) has quietly turned into one of 2025’s wildest biotech comeback stories. After years as a perpetually “promising” RNA interference (RNAi) platform, the company now has:
- Its first FDA‑approved drug on the market
- A fresh FDA Breakthrough Therapy designation in a broader metabolic indication
- A new first‑in‑human Alzheimer’s trial underway
- Multiple big‑pharma partnership checks cleared or on the way
The stock price has responded in full drama mode.
As of the afternoon of December 11, 2025, Arrowhead shares are trading around $70, having touched intraday highs above $72 and notching a new 52‑week high in the low‑$70s. [1] Over the last month, the stock has climbed from the low‑$40s to roughly $70 — a gain on the order of three‑quarters in just a few weeks. [2]
At today’s levels, Arrowhead’s market capitalization is about $9.6 billion, more than tripling year‑over‑year. [3]
Here’s what’s driving ARWR’s surge, and how analysts see the stock after this big run.
Arrowhead Pharmaceuticals Stock Today: A Breakout After a Transformative Year
By multiple measures, Arrowhead is in a very different place than it was even six months ago.
- Price & range: Data from Investing.com show Arrowhead trading around $70 on December 11, with a 52‑week range of roughly $9.57 to $72.36. [4]
- Fresh high: Investing.com and other outlets flagged a new 52‑week high around $71–72 earlier in the day. [5]
- Market cap: StockAnalysis estimates the company’s market value at about $9.6 billion as of December 11, up more than 300% from a year ago. [6]
The move hasn’t been a smooth diagonal line. MarketBeat noted a nearly 6% single‑day drop on December 5 when the stock briefly cooled off, even as the market cap hovered around $8.3 billion. [7] A few days later, Investing.com reported a ~15% intraday jump after new clinical news. [8]
This is classic mid‑cap biotech behavior: big swings tied tightly to clinical and regulatory catalysts.
Catalyst #1: First FDA Approval – Redemplo (Plozasiran) for FCS
The single biggest structural change for Arrowhead in 2025 is straightforward: it’s no longer just a development‑stage story.
On November 18, 2025, the U.S. FDA approved Redemplo (plozasiran), Arrowhead’s RNAi drug targeting apolipoprotein C‑III, to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). [9]
Key points from the approval:
- Indication: Extremely rare genetic disorder (FCS) marked by very high triglyceride levels and recurrent, sometimes life‑threatening pancreatitis. Estimated 3,000–5,000 patients globally. [10]
- Efficacy: In a late‑stage trial with 75 patients, Redemplo cut triglycerides by about 80% and reduced pancreatitis risk by ~83% versus placebo. [11]
- Positioning: It’s just the second FDA‑approved treatment for FCS, competing with Ionis Pharmaceuticals’ Tryngolza. [12]
- Commercial expectations: Analyst consensus compiled by LSEG (via Reuters) points to potential $1.4 billion in annual Redemplo sales by 2031, despite the tiny patient pool, thanks to likely premium pricing. [13]
Arrowhead’s own pipeline page now lists plozasiran as “in market” for FCS, confirming the shift from pure R&D to commercial operations. [14]
From a stock perspective, this matters for three reasons:
- De‑risking the platform: Regulators have now signed off on the company’s core RNAi chemistry in a real indication.
- Revenue line of sight: Although fiscal 2025 revenue was almost entirely from collaboration and milestone payments (not product sales), Redemplo gives Arrowhead a pathway to recurring, high‑margin drug revenue. [15]
- Strategic leverage: Arrowhead has partnered with Sanofi for Greater China rights to Redemplo, which can help with both commercialization and global reach. [16]
There is a catch: FCS is rare, so Redemplo’s current commercial opportunity is limited. The real upside is what happens when the same molecule is pushed into larger triglyceride and dyslipidemia populations.
Catalyst #2: Breakthrough Therapy Designation for Severe Hypertriglyceridemia
Just weeks after approval in FCS, the FDA turned around and granted Breakthrough Therapy designation to plozasiran for severe hypertriglyceridemia (SHTG), where triglycerides are ≥ 500 mg/dL. [17]
Highlights:
- Population size: Instead of a few thousand global FCS patients, SHTG affects millions of people worldwide, many of whom have limited treatment options and elevated cardiovascular and pancreatitis risk. [18]
- Regulatory boost: Breakthrough designation is meant to speed development and review of therapies that may offer substantial improvement over existing options.
Arrowhead is currently running multiple late‑stage studies of plozasiran in SHTG and related dyslipidemias:
- SHASTA‑3 & SHASTA‑4 (Phase 3) in severe hypertriglyceridemia
- MUIR (Phase 2/3) in mixed dyslipidemia
The company has told investors it aims to complete these Phase 3 programs by mid‑2026 and submit a supplemental New Drug Application (sNDA) by year‑end 2026, targeting label expansions beyond ultra‑rare FCS. [19]
If Redemplo can move from a few thousand patients to a much broader SHTG population, Arrowhead begins to look like a cardiometabolic franchise rather than a single‑orphan drug story.
Catalyst #3: RNAi Push Into Alzheimer’s and Brain Diseases – ARO‑MAPT
Arrowhead isn’t just going after the liver and blood lipids anymore.
On December 8, 2025, the company announced that it has initiated a Phase 1/2a trial of ARO‑MAPT, an investigational RNAi therapy targeting tau for Alzheimer’s disease and other tauopathies. [20]
Investing.com reported that the stock jumped around 15% intraday after Arrowhead said it had dosed the first patients in the study. [21]
What makes ARO‑MAPT notable:
- It’s the first Arrowhead drug to use a new proprietary delivery system designed to cross the blood–brain barrier after a subcutaneous shot – a holy‑grail challenge in neurology drug development. [22]
- Preclinical data showed deep knockdown of target genes across the central nervous system, including deep brain regions. [23]
Whether ARO‑MAPT ultimately works in humans is an open question, but the trial sends a signal: Arrowhead wants to extend its RNAi platform well beyond liver‑only indications.
Catalyst #4: Big‑Pharma Deals – Novartis, Sarepta and More
A huge part of Arrowhead’s 2025 rally is “show me the money” from partners:
- Novartis deal (September 2025):
Arrowhead licensed its neuromuscular RNAi therapy ARO‑SNCA to Novartis in a deal worth up to $2 billion, including $200 million upfront and future milestone and royalty payments. [24] - Sarepta milestone (late 2025):
Arrowhead received a $200 million milestone payment from Sarepta for a muscular dystrophy candidate licensed in 2024. An LA Business Journal feature noted that Arrowhead shares were up about 62% over a two‑week span around that time, despite a prior 22% hit tied to deaths in an unrelated Sarepta program. [25]
These deals are important for three reasons:
- They dramatically increased 2025 revenue, which exploded to around $829 million versus $3.6 million in fiscal 2024, mostly from collaboration and milestone payments with Sarepta, Sanofi and GSK. [26]
- They validate Arrowhead’s platform in the eyes of big‑pharma partners with real balance sheets.
- They give Arrowhead cash runway to pursue its own programs — though the company still taps the capital markets (more on that in a moment).
Fresh from the Tape: RBC, BofA and Others Raise ARWR Price Targets
As the catalysts piled up, Wall Street analysts started upgrading their models.
- On December 11, 2025, RBC Capital raised its Arrowhead price target from $52 to $80 while reiterating an “Outperform” rating. [27]
- On December 9, BofA Securities boosted its target from $62 to $81, maintaining a “Buy” rating. [28]
- HC Wainwright nudged its target from $80 to $85 and kept a “Buy” rating on December 2. [29]
- Chardan Capital has a $60 target with a “Buy” stance. [30]
Aggregator data paint a mixed but mostly bullish picture:
- Nasdaq’s compilation of analysts puts the average one‑year price target around $59.24, with a range from roughly $17 to $89, based on data through December 6. [31]
- StockAnalysis lists 10 covering analysts with a “Strong Buy” consensus and an average target of about $60.7, implying mid‑teens downside from today’s price, but a high target of $85 that assumes further upside. [32]
The key nuance: average targets have not yet fully caught up with the rapid stock move from the $40s to $70 in a few weeks. Older targets built on lower share prices still drag the average down even as firms like RBC and BofA chase performance higher.
Short version:
- Sentiment: Skews bullish, with multiple fresh “Buy/Outperform” calls and raised targets. [33]
- Numbers: Average price targets are clustered in the high‑$50s to low‑$60s, below the current ~$70, which hints at the risk that valuation has run ahead of the Street’s base cases.
Financial Picture: Revenue Explosion, Losses Nearly Gone
Arrowhead’s fiscal 2025 results (year ended September 30, 2025) show how much the company’s profile has shifted.
According to company filings and earnings coverage:
- Revenue:
- Fiscal 2025 revenue was about $829–829.4 million, up from roughly $3.6 million in fiscal 2024. [34]
- The jump was driven mainly by license and collaboration revenue (not yet drug sales), with an estimated $300 million milestone from Sarepta and $200 million upfront from Novartis among the major contributors. [35]
- Profitability:
- Balance sheet:
Analysts and platforms like Yahoo Finance and ChartMill describe this as a “transformative” year, with Arrowhead transitioning from heavy losses and minimal revenue to near‑break‑even on the back of partnership inflows and its first approval. [40]
That said, recurring product revenue from Redemplo is only just beginning. The sustainability of these numbers will eventually depend on:
- The launch trajectory in FCS
- Future label expansions in SHTG and broader dyslipidemia
- Progress and potential deals around other assets like Zodasiran and ARO‑MAPT [41]
Capital Moves: Mixed Shelf Filing and Insider Activity
Arrowhead is also making sure it has plenty of financial flexibility.
On December 11, 2025, StreetInsider reported that Arrowhead filed a “mixed shelf” registration covering common stock, preferred stock, debt securities and warrants. [42]
A universal shelf doesn’t mean an immediate offering, but it does mean:
- The company can raise capital quickly through stock or debt if it wants to accelerate trials, manufacturing, or commercialization.
- Investors have to factor in potential dilution if substantial equity is sold at or near current prices.
Separately, TipRanks highlighted an insider sale by director Mauro Ferrari on December 1, 2025. [43] Insider selling isn’t automatically bearish — directors diversify for all sorts of reasons — but with the stock near highs, some investors will read it as a reminder not to assume a straight line up.
The Broader Pipeline: Zodasiran and Beyond
Arrowhead’s late‑stage pipeline is increasingly cardiometabolic‑heavy:
- Plozasiran (Redemplo):
- Zodasiran (ARO‑ANG3):
- Phase 3 YOSEMITE trial underway in homozygous familial hypercholesterolemia (HoFH), another rare but serious lipid disorder with very high LDL‑C and early cardiovascular disease. [47]
This gives Arrowhead a multi‑asset, late‑stage cardiometabolic portfolio: high triglycerides (plozasiran), extreme LDL‑C (zodasiran), and a framework for further expansion into broader lipid disorders.
Key Risks: Volatility, Litigation, Dilution and Clinical Uncertainty
For all the excitement, Arrowhead remains a high‑risk biotech stock. Some of the main risk flags:
- Sharp volatility
- Articles from outlets like Simply Wall St and various trading platforms have noted double‑digit daily moves — for instance, ARWR rose about 22% after the plozasiran Breakthrough designation, and has also dropped ~6% in a single session when sentiment turned. [48]
- Short interest remains material, and quant tools that focus on momentum (e.g., certain StreetInsider metrics) still flash caution despite the fundamental upgrades. [49]
- Patent litigation with Ionis
- Ionis has sued Arrowhead, alleging Redemplo infringes its RNA‑targeting patents; Arrowhead is seeking a ruling that the Ionis patent is invalid. [50]
- Legal outcomes are unpredictable, and large judgments or restrictions could impact economics around Redemplo.
- Clinical and regulatory risk
- The Breakthrough designation and early‑stage CNS work are promising but not guarantees. Failures in SHASTA‑3/4, MUIR, ARO‑MAPT, or Zodasiran could materially hit sentiment and future revenue potential. [51]
- Commercial execution risk
- FCS is ultra‑rare. Analysts expect blockbuster‑level revenue by 2031, but that depends on pricing, payer coverage, physician adoption, and competition from Ionis’ Tryngolza and possibly future entrants. [52]
- Financing and dilution
- The new mixed shelf registration increases the odds of equity or debt offerings, especially if Arrowhead wants to fully self‑fund large Phase 3 trials and commercial launches. [53]
Biotech investors live with these risks all the time, but after a move of this magnitude, even routine disappointments can translate into large drawdowns.
Arrowhead Pharmaceuticals Stock Outlook
Putting it all together:
- Story shift: Arrowhead has moved from small‑cap, high‑risk pipeline optionality to mid‑cap commercial‑stage biotech with a validated RNAi platform, a first product on the market, and multiple late‑stage programs targeting significant metabolic disease markets. [54]
- Near‑term drivers (next 6–18 months):
- Redemplo launch metrics in FCS
- Enrollment and interim updates from SHASTA‑3/4 and MUIR
- Early safety/PK/PD readouts from the ARO‑MAPT Alzheimer’s program
- Progress in the Zodasiran YOSEMITE Phase 3 study for HoFH
- Any new licensing or co‑development deals
- Valuation context:
- The stock is now trading above most legacy analyst price targets, but recently increased targets (e.g., $80–$85 from RBC, BofA, HC Wainwright) imply that some on the Street still see upside, especially if label expansions and neurology programs pan out. [55]
For traders, ARWR is likely to remain a news‑driven, high‑beta vehicle where each data point or regulatory update can swing the price. For longer‑term biotech investors who believe in the RNAi cardiometabolic thesis, Arrowhead has quickly become one of the more strategically central, but also richly valued, names in the space.
Either way, this is no longer a quiet small‑cap science project. As of December 11, 2025, Arrowhead Pharmaceuticals is on the main stage — with all the scrutiny, risk, and opportunity that implies.
References
1. www.investing.com, 2. www.investing.com, 3. stockanalysis.com, 4. www.investing.com, 5. www.investing.com, 6. stockanalysis.com, 7. www.marketbeat.com, 8. m.investing.com, 9. www.reuters.com, 10. www.reuters.com, 11. www.reuters.com, 12. www.reuters.com, 13. www.reuters.com, 14. arrowheadpharma.com, 15. www.nasdaq.com, 16. www.reuters.com, 17. www.businesswire.com, 18. www.businesswire.com, 19. ir.arrowheadpharma.com, 20. www.businesswire.com, 21. m.investing.com, 22. www.businesswire.com, 23. www.businesswire.com, 24. www.reuters.com, 25. labusinessjournal.com, 26. www.nasdaq.com, 27. www.marketscreener.com, 28. www.gurufocus.com, 29. www.gurufocus.com, 30. www.gurufocus.com, 31. www.nasdaq.com, 32. stockanalysis.com, 33. www.gurufocus.com, 34. www.nasdaq.com, 35. www.chartmill.com, 36. www.nasdaq.com, 37. www.tipranks.com, 38. www.nasdaq.com, 39. www.nasdaq.com, 40. www.chartmill.com, 41. arrowheadpharma.com, 42. www.streetinsider.com, 43. www.tipranks.com, 44. arrowheadpharma.com, 45. arrowheadpharma.com, 46. arrowheadpharma.com, 47. arrowheadpharma.com, 48. simplywall.st, 49. www.streetinsider.com, 50. www.reuters.com, 51. arrowheadpharma.com, 52. www.reuters.com, 53. www.streetinsider.com, 54. www.nasdaq.com, 55. www.gurufocus.com
